AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2017
Aug 2, 2017
29864_dirs_2017-08-02_e78e5dee-d9c2-4f35-a06e-e73daa0eaf30.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2017-07-31
Reporting Person: LEIDEN JEFFREY M (Director, CEO & President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-07-31 | Common Stock | M | 11063 | $45.11 | Acquired | 268455 | Direct |
| 2017-07-31 | Common Stock | S | 5363 | $152.25 | Disposed | 263092 | Direct |
| 2017-07-31 | Common Stock | S | 5000 | $153.24 | Disposed | 258092 | Direct |
| 2017-07-31 | Common Stock | S | 700 | $154.05 | Disposed | 257392 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-07-31 | Stock Option (Right to Buy) | $45.11 | M | 11063 | Disposed | 2023-02-04 | Common Stock (11063) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 440 | Indirect |
Footnotes
F1: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $152.25 (range $151.79 to 152.77).
F3: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $153.24 (range $152.79 to $153.78).
F5: Open market sales reported on this line occurred at a weighted average price of $154.05 (range $153.91 to $154.27).
F6: Fully vested.